Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis Therapy
Study data from R. Ruslami and co-authors update knowledge of tuberculosis therapy
August 27th, 2007
Fresh data on tuberculosis are presented in the report "Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Rifampin is a key drug for tuberculosis (TB) treatment. The available data suggest that the currently applied 10-mg/kg of body weight dose of rifampin may be too low and that increasing the dose may shorten the treatment duration," scientists writing in the journal Antimicrobial Agents and Chemotherapy report. "A double-blind randomized phase II clinical trial was performed to investigate the effect of a higher dose of rifampin in terms of pharmacokinetics and tolerability. Fifty newly...
Source: Clinical Trials Week (2007-08-27)
|
